Company Encyclopedia
View More
name
Small Growth
CP99104.HK
News
View More

China expects industrial output to have grown 5.9% in 2025

China's industry ministry anticipates a 5.9% growth in industrial output for large companies in 2025, slightly up from 5.8% in 2024. This growth is below the 6% pace of the first eleven months of 2025. Analysts suggest government action to boost domestic demand and address the property crisis. Policymakers plan fiscal measures to enhance consumption and investment.

Businesstimes·
HK
02025
+0.95%
Businesstimes·
HK
02025
+0.95%

China to enforce new EV energy consumption standard in 2026, capping 2-ton models at 15.1 kWh/100 km

China will enforce its first mandatory national standard on energy consumption for electric vehicles starting January 1, 2026. The standard sets limits on electricity consumption for pure electric passenger vehicles, capping 2-ton models at 15.1 kWh/100 km. Automakers must upgrade technology to meet these requirements, which are expected to increase EV driving range by about 7%.

动点科技英文源·
HK
02026
-1.40%
动点科技英文源·
HK
02026
-1.40%

Keymed Biosciences, Inc. (2162) Receives a Buy from Sinolink Securities

Sinolink Securities analyst maintained a Buy rating on Keymed Biosciences, Inc. yesterday and set a price target of HK$83.29.Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Keymed Biosciences, Inc. has an analyst consensus of Strong Buy, with a price target consensus of HK$88.61.

Tip Ranks·
HK
02162
-1.28%
Tip Ranks·
HK
02162
-1.28%

China’s rising biotech clout on show in flurry of billion-dollar licensing deals

Chinese biotech firms are increasingly engaging in billion-dollar out-licensing deals with multinational pharmaceutical companies. Jacobio Pharmaceuticals and Coherent Biopharma have recently signed significant agreements with AstraZeneca and MultiValent Biotherapies, respectively, highlighting China's growing influence in novel medicine development. These deals reflect a trend of global drugmakers seeking Chinese biotech innovations amid pricing pressures and patent expiries. China's supportive policies for biopharmaceuticals further bolster this trend.

南华早报·
HK
01167
+2.56%
UK
AZN
0.00%
US
AZN
+0.22%
南华早报·
HK
01167
+2.56%
UK
AZN
0.00%
US
AZN
+0.22%

Humanoid Robots: AI's Best Hope?

Entering 2025, three years into the OpenAI-led AI cycle, the industry remains in a full-on AI investment phase. Based on our recent work, Dolphin Research sees 2026 hinging on compute cost-down and on AI capex translating into deployments across software and hardware.The rollout of new hardware is the true incremental driver. Meanwhile, mass production of Tesla's Optimus is drawing closer, and humanoid robots could become the primary AI form factor, reshaping human interaction and productivity.On this premise, Dolphin Research is launching coverage on the robotics supply chain. This is Part 1.

HK
02498
+2.32%
SH
605488
-2.25%
SH
688322
+1.42%
HK
02498
+2.32%
SH
605488
-2.25%
SH
688322
+1.42%
Posts
View More

$XTALPI(02228.HK) has completely lost momentum. Everyone, take a break, it's holiday time! 😂

$XTALPI(02228.HK) With today's liquidity, it feels like the market makers didn't show up for work. Fine, let's call it an early holiday.

$Rocket Lab(RKLB.US)$Tesla(TSLA.US)$XTALPI(02228.HK)

Good Morning!

Good Afternoon!

Good Night!

  • 0
© 2025 Longbridge｜Disclaimer